FH Foundation’s FOCUS analysis shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates


Pasadena, Calif. – The Familial Hypercholesterolemia Foundation today published a study in Circulation revealing high rejection rates for PCSK9 inhibitors in the two at-risk patient populations approved for this novel cholesterol-lowering class of therapy.

The FH Foundation’s FOCUS (FH Optimal … Read More